ANKL is a rare and aggressive type of blood cancer affecting a type of white blood cell called natural killer (NK) cells. In ANKL, the NK cells are abnormal and multiply out of control,...
Aggressive NK-cell leukemia (ANKL) is a rare NK-cell leukemia characterized by, an aggressive clinical course, and frequent Epstein–Barr virus association.
Aggressive natural killer (NK) cell leukemia (ANKL) is a rare disease with a grave prognosis. Patients commonly present acutely with fever, constitutional symptoms, hepatosplenomegaly, and often disseminated intravascular coagulation or hemophagocytic syndrome.
ANKL is extremely rare, with fewer than 100 cases reported globally each year. It is most prevalent in East Asia, particularly in countries like Japan, Korea, and China, but it can affect individuals of any ethnicity.
Aggressive natural killer cell leukaemia (ANKL) is a rare, fast growing blood cancer. Find out what it is, signs and symptoms it can cause, how it’s diagnosed and common treatment options.
ANKL is almost always associated with Epstein-Barr virus (EBV) infection. EBV plays a role in the pathobiology of ANKL and is considered responsible for its aggressive clinical features.
NK-cell Origin: ANKL arises from malignant transformation of natural killer cells, a subset of lymphocytes involved in innate immunity and anti-tumor responses.
Aggressive natural killer cell leukemia (ANKL) is a rare hematologic malignancy characterized by the EBV-driven proliferation of mature natural killer cells. It mostly frequently affects younger adults and has a fulminant course with a median overall survival of 2 months.
As rare EBV negative ANKL have been described, EBV negative status cannot be used as the sole criterion to exclude a diagnosis of ANKL Bone marrow involvement by ANKL can be prominent or subtle